Robin Swartz
Net worth: 767 788 $ as of 30/09/2026
Net worth: 767 788 $ as of 30/09/2026
Mr. Robin Swartz is a Chief Operating Officer & Business Officer at Voyager Therapeutics, Inc. Mr. Swartz was previously employed as a Vice President-Product Services by Genzyme Therapeutics Ltd. and a Vice President-Patient & Product Services by Genzyme Corp.
He also served on the board at Sanofi-Aventis, Inc. He received his undergraduate degree from Kenyon College.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2026 | 2,86,488 ( 0.46% ) | 767 788 $ | 30/09/2026 |
| Companies | Position | Start |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Chief Operating Officer | 01/02/2022 |
| Companies | Position | End |
|---|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/06/2020 |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Director/Board Member | - |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Kenyon College
Kenyon College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions